Preeclampsia Diagnostics Market Size to Exceed USD 4.60 Bn by 2032

The Preeclampsia Diagnostics Market, estimated at USD 2.32 Bn in 2025, is expected to exhibit a CAGR of 10.3% and reach USD 4.60 Bn by 2032.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

Market Dynamics:

Global preeclampsia diagnostics market growth is primarily driven by increasing healthcare expenditure and rising prevalence of gestational hypertension across the globe. Growing healthcare expenditure has enabled better access to advanced diagnostic technologies for early detection of preeclampsia. According to the World Bank, global healthcare expenditure witnessed a growth of 6.5% in 2020 reaching USD 8.3 trillion. Furthermore, increasing prevalence of gestational hypertension is also expected to boost demand for preeclampsia diagnostic tools. As per the World Health Organization (WHO), hypertensive disorders including preeclampsia affects approximately 10% of pregnancies worldwide annually. Early diagnosis of preeclampsia is important to prevent life-threatening complications for both mother and baby. This has resulted in increased adoption of innovative diagnostic devices in modern healthcare facilities. Rapid advancements in proteomic and genomic diagnostic technologies are further expected to drive the market growth during forecast period.

Rising incidence of preeclampsia and gestational hypertension

Rising incidence of preeclampsia and gestational hypertension can drive the market growth. According to the Centers for Disease Control and Prevention (CDC), the rate of preeclampsia in the U.S. had increased by 25% between 1987 and 2004. The exact cause for this disorder is unclear but factors such as increasing maternal age, obesity, chronic hypertension and diabetes can contribute to higher risk. As the number of women experiencing these conditions increases, the need for accurate diagnostic testing also increases.

Advancements in screening and diagnostic technologies

Significant advancements are being made in the development of novel screening tools and diagnostic biomarkers for early and accurate detection of preeclampsia. Researchers are developing new technologies for non-invasive prenatal testing of placental microparticles in maternal blood to detect early signs of preeclampsia. Companion diagnostics are also being incorporated to stratify risk and guide clinical management. Next-generation sequencing approaches are elucidating the genetic factors involved which may lead to personalized screening approaches. The introduction of these advanced screening and diagnostic solutions is expected to boost demand for preeclampsia diagnostics.

Low adoption in low and middle-income countries

While the diagnostics market is growing in developed nations, there is low adoption of preeclampsia diagnostics in emerging economies where the majority of preeclampsia cases occur. Factors such as lack of awareness, limited funding for healthcare, and inadequate infrastructure restrict widespread use of advanced tests. Many regions still rely on less effective clinical monitoring for diagnosis. The huge burden in developing nations represents untapped market potential but commercialization challenges must be overcome to realize gains. Addressing availability and affordability hurdles is critical to mitigating this restraint.

High cost of novel technologies

Development of innovative screening tools and biomarkers requires significant investment in R&D. This high input cost is eventually passed on to patients and healthcare systems utilizing the new technologies. While early diagnosis improves outcomes, high cost can limit broader adoption especially in cost-sensitive markets. Reimbursement challenges further inhibit market access for high-end offerings in several regions. Achieving economies of scale and demonstrating clear clinical utility and cost-effectiveness can overcome this restraint over the long term.

Expanding indications for emerging biomarkers

New biomarkers not only enables early preeclampsia diagnosis but also provides insights into disease etiology, predicting severity, and monitoring response to treatment. This expanded clinical utility represents an opportunity to drive repeat testing and capture additional revenue streams beyond initial diagnosis. As validation studies progress, a growing array of actionable indications could support sustained market growth. Biomarker developers focusing on multi-purpose solutions can  gain significant advantages.

Integration with digital health platforms

Digital health and telemedicine are transforming prenatal care delivery models. Remote patient monitoring, AI-powered risk calculators, electronic health records and mHealth tools are enhancing diagnosis, clinical decision-making and disease management. Incorporating emerging preeclampsia diagnostics into digital platforms allows for more convenient, accessible testing as well as automated data capture, analysis and reporting capabilities. Partnerships that facilitate seamless integration with virtual care solutions can help expand market reach, uptake and adherence especially in underserved populations.

Link: https://www.coherentmarketinsights.com/market-insight/preeclampsia-diagnostics-market-4606

Key Development

• On January 31, 2024, Labcorp, a provider of laboratory services, launched an U.S. FDA-cleared blood test for severe preeclampsia risk assessment and management. Developed by Thermo Fisher Scientific, the test measures two biomarkers associated with preeclampsia and was named one of TIME Magazine's Best Inventions of 2023.
• In July 2023, an U.S. FDA-approved blood test, developed by Thermo Fisher Scientific, a pharmaceutical and biotechnology company that accurately predicts preeclampsia within two weeks with a 96% success rate, was praised by experts such as Dr. Douglas Woelkers from the University of California, San Diego
• In May 2023, CSEM, a technology innovation center, its Tools for Life Sciences division collaborated with MOMM Diagnostics, a company that develops a rapid diagnostic test for the detection of preeclampsia - a dangerous pregnancy condition. to create an innovative point-of-care solution for preeclampsia diagnosis. This advanced sensing device simultaneously identifies two key biomarkers linked to this common condition, representing a significant breakthrough in diagnostics.
• In July 2021, LifeCell Diagnostics, a biotechnology company, introduced a comprehensive preeclampsia screening program in India. This initiative aims to detect the biomarker sFLT-1 (soluble FMS-like tyrosine kinase-1), enabling early prediction and accurate diagnosis of the condition, even during the third trimester of pregnancy.

Key Players: Roche Diagnostic, Thermo Fisher Giving Inc., PerkinElmer, Siemens Healthineers, Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company (BD), bioMérieux, F. Hoffmann-La Roche Ltd, Metabolomic Diagnostics Ltd, Diabetomics, Inc., Quidel Corporation, Sera Prognostics, Brahms GmbH, The Progenix Group